Marksans Pharma is the top gainer on the BSE Sensex currently; volumes have jumped on the counter by over 7 times and the stock price, intra day, rose almost 17% at Rs.56.25, getting so close to its 52-week high of Rs.58.30.

The stock is up after the company said that its Goa plant has been approved by UK MHRA. The plant was inspected between February 14-17. This means that the company can start supplying all drugs to the UK.

Marksans Pharma is engaged in the research, manufacturing and marketing of generic pharmaceutical formulations. The company's product portfolio addresses various therapeutic segments, including pain management, cough and cold, anti-diabetic, cardiovascular system, central nervous system, antibiotic, gastrointestinal, anti-allergic and others.